James Scopa - TriVascular Technologies Independent Director
Director
Mr. James P. Scopa is Independent Director of TriVascular Technologies Inc. Mr. Scopa is a Managing Director in MPM Capitals San Francisco office having joined the firm in 2005. Previously Mr. Scopa spent 18 years advising growth companies in biopharmaceuticals and medical devices at Deutsche Banc Alex. Brown and Thomas Weisel Partners. At Deutsche Banc Alex. Brown he served as Managing Director and Global CoHead of Healthcare Investment Banking. At Thomas Weisel Partners he served on the Investment Committee for TWPs Health Care venture fund as well as CoDirector of Healthcare Investment Banking. Mr. Scopa currently serves on the boards of directors of Conatus Inc. and five additional private companies since 2008.
| Age | 55 |
| Tenure | 16 years |
| Professional Marks | MBA |
| Phone | 707-543-8800 |
| Web | http://www.trivascular.com |
TriVascular Technologies Management Efficiency
The company has return on total asset (ROA) of (0.574) % which means that it has lost $0.574 on every $100 spent on assets. This is way below average. TriVascular Technologies' management efficiency ratios could be used to measure how well TriVascular Technologies manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 55 M in liabilities with Debt to Equity (D/E) ratio of 1.74, which is about average as compared to similar companies. TriVascular Technologies has a current ratio of 6.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist TriVascular Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, TriVascular Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like TriVascular Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for TriVascular to invest in growth at high rates of return. When we think about TriVascular Technologies' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Anderson | Commonwealth Bank of | 68 | |
| Laurence Zipkin | Mill City Ventures | 74 | |
| Douglas Clemens | Univest Pennsylvania | 59 | |
| Annie Goodwin | Glacier Bancorp | 62 | |
| Paul Shelly | Univest Pennsylvania | 70 | |
| George Sutton | Glacier Bancorp | 72 | |
| Bradley Maiorino | NETGEAR | 47 | |
| Wendy Stops | Commonwealth Bank of | 56 | |
| William Morral | Univest Pennsylvania | 70 | |
| Dallas Herron | Glacier Bancorp | 73 | |
| Paul OMalley | Commonwealth Bank of | N/A | |
| Jef Graham | NETGEAR | 60 | |
| Lee Delp | Univest Pennsylvania | 70 | |
| Mark Schlosser | Univest Pennsylvania | 51 | |
| Joseph Geraci | Mill City Ventures | 44 | |
| Brian Long | Commonwealth Bank of | 71 | |
| Natalye Paquin | Univest Pennsylvania | 57 | |
| Shirish Apte | Commonwealth Bank of | 64 | |
| Howard Liszt | Mill City Ventures | 67 | |
| Julie Shimer | NETGEAR | 65 | |
| Todd Benning | Univest Pennsylvania | 57 | |
Management Performance
| Return On Asset | -0.57 |
TriVascular Technologies Leadership Team
Elected by the shareholders, the TriVascular Technologies' board of directors comprises two types of representatives: TriVascular Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of TriVascular. The board's role is to monitor TriVascular Technologies' management team and ensure that shareholders' interests are well served. TriVascular Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, TriVascular Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jake Nunn, Independent Director | ||
| Christopher Chavez, Chairman, CEO and Pres | ||
| Ryan Drant, Independent Director | ||
| Michael Kramer, CFO and Principal Accounting Officer | ||
| Kimberley Elting, Chief Compliance Officer, VP of Corporate Affairs, General Counsel and Secretary | ||
| Daniel Moore, Independent Director | ||
| James Scopa, Independent Director | ||
| Vivek Jayaraman, Vice President - Global Sales and Marketing | ||
| Louis Molinari, Vice President - Manufacturing Operations | ||
| Robert Whirley, Co-Founder and VP of RandD | ||
| Robert Thomas, Independent Director | ||
| Michael Chobotov, Co-Founder and CTO | ||
| Douglas Roeder, Independent Director | ||
| Shari OQuinn, Vice President - Clinical/Regulatory Affairs and Quality |
TriVascular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is TriVascular Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.57 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 217.63 M | |||
| Shares Outstanding | 14.52 M | |||
| Shares Owned By Insiders | 28.43 % | |||
| Shares Owned By Institutions | 64.30 % | |||
| Number Of Shares Shorted | 226.84 K | |||
| Price To Earning | (3.18) X | |||
| Price To Book | 88.33 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in TriVascular Stock
If you are still planning to invest in TriVascular Technologies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TriVascular Technologies' history and understand the potential risks before investing.
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |